BiotechTube

Ad-RTS-hIL-12 + Veledimex + Cemiplimab-Rwlc

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 17/100
17
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Glioblastoma

Conditions

Glioblastoma

Trial Timeline

Aug 1, 2019 → Aug 5, 2021

NCT ID
NCT04006119

About Ad-RTS-hIL-12 + Veledimex + Cemiplimab-Rwlc

Ad-RTS-hIL-12 + Veledimex + Cemiplimab-Rwlc is a phase 2 stage product being developed by Alaunos Therapeutics for Glioblastoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT04006119. Target conditions include Glioblastoma.

What happened to similar drugs?

1 of 18 similar drugs in Glioblastoma were approved

Approved (1) Terminated (1) Active (16)
✅TemozolomideMerckApproved
🔄enzastaurin + lomustineEli LillyPhase 3
🔄DSP-7888 Dosing Emulsion + BevacizumabSumitomo PharmaPhase 3
🔄Temozolomide + Depatuxizumab mafodotin + Placebo for ABT-414AbbViePhase 3
❌Steroid eye drops + Vasoconstrictor eye drops + Ophthalmic steroid ointment + Depatuxizumab mafodotin + TemozolomideAbbViePhase 3
🔄Cediranib + Cediranib + Lomustine Chemotherapy + Placebo CediranibAstraZenecaPhase 3
🔄Cilengitide + TemozolomideMerckPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04006119Phase 2Terminated

Competing Products

20 competing products in Glioblastoma

See all competitors
ProductCompanyStageHype Score
TemferonGenenta SciencePhase 1/2
26
PLX3397 + TemozolomideDaiichi SankyoPhase 1/2
32
PLX3397Daiichi SankyoPhase 2
27
ASP8374 + cemiplimabAstellas PharmaPhase 1
29
Nimotuzumab + TemozolomideSun PharmaceuticalPhase 2
35
Gliadel + Avastin + TemodarEisaiPhase 2
27
BCNU Wafer + Irinotecan + BevacizumabEisaiPhase 1/2
24
KHK2455Kyowa KirinPre-clinical
26
olaratumab + ramucirumabEli LillyPhase 2
35
enzastaurin + temozolomideEli LillyPhase 1/2
32
enzastaurin + bevacizumab + Enzyme-inducing antiepileptic drugs (EIAED) + Non-enzyme inducing antiepileptic drugs (NEIAED)Eli LillyPhase 2
35
Temozolomide + Neratinib + QBS10072S + Abemaciclib + CC-115Eli LillyPhase 2
42
AbemaciclibEli LillyPhase 2
39
Enzastaurin 500 milligram (mg) Once Daily (QD) + Enzastaurin 250 mg Twice Daily (BID)Eli LillyPhase 2
35
Abemaciclib + LY3214996Eli LillyPhase 1
29
enzastaurin + lomustineEli LillyPhase 3
40
Galunisertib + Lomustine + PlaceboEli LillyPhase 2
35
DSP-7888 Dosing Emulsion + BevacizumabSumitomo PharmaPhase 3
40
DSP-7888Sumitomo PharmaPhase 1/2
32
BBI608 + TemozolomideSumitomo PharmaPhase 1/2
32